Antinol for Dog Osteoarthritis: What the Trials Tested and Found
The unresolved field is whether the capsule a dog owner can buy is the capsule that was tested. Two randomized, double-blinded, placebo-controlled trials from one Thai university group found that EAB-277, a combination of krill oil phospholipids and green-lipped mussel lipid fractions, improved limb use over 6 weeks in dogs with hip osteoarthritis (OA). Both trials were short, limited to hip OA in dogs of at least 15 kg, and measured gait with a force plate. Neither tested cats, and neither showed that the products sold under the Antinol name in the United States are the formulation that was tested.
What the controlled trials tested
| Study | Dogs and design | Endpoint | Result | Limits that change interpretation |
|---|---|---|---|---|
| Kampa et al., 2023 (Frontiers in Veterinary Science) | 75 owned dogs with hip OA, randomized to PCSO-524, EAB-277, glucosamine and chondroitin, carprofen or placebo (sunflower oil); 6 weeks | Peak vertical force (PVF) from force-plate gait analysis; orthopedic assessment scores | At 6 weeks, PVF rose 4.45 ± 4.23 with EAB-277, 4.14 ± 4.65 with PCSO-524 and 4.21 ± 6.52 with carprofen, against −0.33 ± 3.65 with placebo; glucosamine and chondroitin fell between at 1.08 ± 5.49; the orthopedic scores showed no significant change in any group | Funded by Pharmalink International Ltd., which the authors say was not involved in design, analysis or the decision to publish; the senior author disclosed past paid consulting for the VetzPetz Asia company, unrelated to payment for this study |
| Kampa et al., 2024 (Frontiers in Veterinary Science) | 101 dogs with hip OA pain, one side worse; randomized to EAB-277 (Antinol Rapid), Biota orientalis extract, meloxicam or placebo; 6 weeks | PVF of the worse limb, orthopedic scores, blood tests | At 6 weeks, PVF rose 3.83 ± 3.08 with EAB-277 and 4.87 ± 3.07 with meloxicam, against −0.77 ± 3.14 with placebo; responders (PVF change above 2%) were 69.23% (18 of 26) with EAB-277, 79.17% (19 of 24) with meloxicam, 40.00% (10 of 25) with the Biota extract and 7.69% (2 of 26) with placebo; blood tests stayed normal and no unexpected adverse events occurred | Protocol written in advance but not publicly registered; no owner-reported outcome measures; overall orthopedic score changes were small on a coarse scale; the authors declare no commercial or financial relationships |
| Hielm-Björkman et al., 2007 (Evidence-Based Complementary and Alternative Medicine) | 45 dogs with hip or elbow OA, randomized to a freeze-dried green-lipped mussel powder (Lyproflex), carprofen or placebo; 8 weeks | Vet-assessed mobility, force plate and owner pain scores | More dogs improved than with placebo on some measures, but the mussel product was not as effective as carprofen | A different product from Antinol: whole freeze-dried mussel, not a lipid extract; products supplied free by the makers, with foundation funding |
Both Kampa trials were designed with a positive control. In the 2024 trial, meloxicam improved limb use earliest, by week 2, and EAB-277 by week 4, and by week 6 the gain with EAB-277 was similar to meloxicam's. The authors write that the minimal clinically important change in PVF has not been defined, and they used a 2% cutoff from earlier work to count responders.
How to read the results
What the trials show is a measurable gain in weight-bearing on the worse hind limb of dogs with hip OA, compared with placebo, after 6 weeks. The gait findings fit the 2023 result, which also reported a gain of about 4 percentage points of body weight with EAB-277.
Several limits narrow what that means. Six weeks says nothing about longer use. The studies enrolled dogs weighing at least 15 kg and aged at least 18 months, with normal blood work and no other analgesics during the trial, so a small dog, a young dog, a dog with another joint problem, or a dog already on an NSAID is outside the studied group. The authors of the 2024 trial note that it did not use owner-reported questionnaires, so how much owners noticed is not measured. The orthopedic score changes were small, and the 2023 trial found no significant change in that score in any group.
Hielm-Björkman's earlier study is a reminder that "green-lipped mussel" can mean different products. A powdered whole mussel and a lipid extract are not the same ingredient, so results for one do not carry over to the other.
Does your capsule match the study capsule?
| Product | Composition per its own listing | Link to the tested product |
|---|---|---|
| Studied product | Antinol Rapid (EAB-277), Pharmalink International; phospholipids from krill oil together with lipid fractions from green-lipped mussel (PCSO-524); given in original manufactured capsules | The tested product |
| Antinol Plus, United States (distributed by Pet HealthWorks, Fort Lauderdale) | Green-lipped mussel oil and Antarctic krill oil; manufactured in the USA; soft gel of bovine gelatin with olive oil, vitamin E, glycerin and sorbitol | The maker's page lists both Kampa trials and says "what you buy is exactly what was studied"; the trial paper names Antinol Rapid, so this is a first-party claim to confirm |
| Antinol Plus, New Zealand | Green-lipped mussel extract 30 mg, krill oil 20 mg, olive oil, vitamin E, gelatin and glycerin | Not stated in the trial papers |
| Antinol, United Kingdom | PCSO-524 50 mg, olive oil, vitamin E, gelatin and glycerin; no krill listed | A different ingredient list from the US product |
The directions, strengths and starting amounts also differ across markets, and none of this article's sources lets a reader transfer a study's amounts to a different product. A listing for dogs and cats under one name can describe different formulations in different countries. The UK maker says its cat capsule uses the same formulation as its dog capsule, but none of the trials read tested cats.
Wrong-fit boundaries and the question to bring
A dog that fits the studied group is one with hip OA, at least 18 months old and at least 15 kg. A dog outside it, or one with a shellfish sensitivity (green-lipped mussel is a shellfish, and the UK maker advises speaking to a veterinarian first), is a case for the veterinarian to weigh. The New Zealand listing also says safety has not been tested in pregnant or lactating animals and that the product may contain a minute amount of tropomyosin.
The trials position EAB-277 as a possible aid for OA pain. They do not replace a diagnosis, pain assessment or the first-line options that guidelines place ahead of it, such as an NSAID or an anti-nerve growth factor antibody. The 2024 paper's own introduction says omega-3 fatty acids are recommended as a first-line non-pharmacological option, and that the supplement market is lightly regulated.
Bring these to the veterinarian: photographs of the package and ingredient panel with the lot number, the dog's age, weight and joint diagnosis, current medicines and supplements, and notes or short videos of how the dog walks, gets up and climbs stairs. The unanswered question is whether the capsule in your hands is the formulation that produced the trial results, and what change in your dog's mobility you would measure, and over how many weeks, to decide whether it is helping.